Florian Nolte

Mannheim, BW 68167, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.

Journal: Annals of hematology

Published: December 19, 2023

Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis.

Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis.

Journal: Case reports in hematology

Published: May 05, 2023

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.

Journal: Nature communications

Published: July 15, 2022

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 20, 2021

The insertion site is the main risk factor for central venous catheter-related complications in patients with hematologic malignancies.

The insertion site is the main risk factor for central venous catheter-related complications in patients with hematologic malignancies.

Journal: American journal of hematology

Published: July 07, 2021

Humanized three-dimensional scaffold xenotransplantation models for myelodysplastic syndromes.

Humanized three-dimensional scaffold xenotransplantation models for myelodysplastic syndromes.

Journal: Experimental hematology

Published: April 07, 2021

Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.

Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.

Journal: Leukemia

Published: February 15, 2021

Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo.

Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo.

Journal: Nature communications

Published: January 26, 2021

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).

Journal: Annals of hematology

Published: November 17, 2020

Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.

Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.

Journal: Cancers

Published: November 03, 2020

High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes.

High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes.

Journal: British journal of haematology

Published: October 11, 2020

Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations.

Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations.

Journal: Haematologica

Published: September 10, 2020

Showing 1-12 of 59

Last Updated: 09/26/2026